Benefits of IV Stem Cell Therapy for Lupus Patients

Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus

First published: 03 August 2010



Umbilical cord (UC)–derived mesenchymal stem cells (MSCs) have shown marked therapeutic effects in a number of diseases in animal studies, based on their potential for self‐renewal and differentiation. No data are available on the effectiveness of UC MSC transplantation (MSCT) in human autoimmune disease. This study was undertaken to assess the efficacy and safety of allogeneic UC MSCT in patients with severe and treatment‐refractory systemic lupus erythematosus (SLE).


We conducted a single‐arm trial that involved 16 SLE patients whose disease was refractory to standard treatment or who had life‐threatening visceral involvement. All of the patients gave consent and underwent UC MSCT. Clinical changes were evaluated before and after transplantation using the SLE Disease Activity Index (SLEDAI), measurement of serum antinuclear antibody (ANA), anti–double‐stranded DNA (anti‐dsDNA) antibody, serum complement C3 and C4, and albumin levels, and assessment of and renal function. Evaluation of potential mechanisms of MSCT effects focused on the percentage of peripheral blood Treg cells and serum levels of cytokines.


From April 2007 to July 2009, a total of 16 patients with active SLE were enrolled and underwent UC MSCT. The median followup time after MSCT was 8.25 months (range 3–28 months). Significant improvements in the SLEDAI score, levels of serum ANA, anti‐dsDNA antibody, serum albumin, and complement C3, and renal function were observed. Clinical remission was accompanied by an increase in peripheral Treg cells and a re‐established balance between Th1‐ and Th2‐related cytokines. Significant reduction in disease activity was achieved in all patients, and there has been no recurrence to date and no treatment‐related deaths.


Our findings indicate that UC MSCT results in amelioration of disease activity, serologic changes, and stabilization of proinflammatory cytokines. These data provide a foundation for conducting a randomized controlled trial of this new therapy for severe and treatment‐refractory SLE.

Authors:  , Dandan Wang, et al. 

Dr. Clark H. Hansen Dr. Clark H. Hansen is a licensed Naturopathic Medical Doctor (N.M.D.) who has been in private practice in Scottsdale, Arizona, since 1986. He is the President and Medical Director of the Hansen Clinic of Natural Medicine, Aesthetics and Mesotherapy. Dr. Hansen is one of the most well respected Naturopathic Physicians in the country and a Diplomat of the World Society of Anti-Aging Medicine.

You Might Also Enjoy...

Stem Cell Therapy Overview - Regenerate a New You!

Stem Cells are the body's Restore or Replace secret weapon. They can change into any type of cell that the body needs to supplement, restore, reconstruct or replace damaged cells, including Joints, Bones, Heart, Muscle, Nerves, Organs & Skin.

Stem Cell Therapy for STROKE Recovery

Stem Cell Therapy for Strokes may revolutionize how we treat not only stroke, but traumatic brain injury and even neurodegenerative disorders. The notion that once the brain is injured, it doesn't recover, has now been proven false.

Top Ten Reasons NOT to have Total Knee Replacement Surgery

It is estimated that at least 27 million people are affected by arthritis in the US, with an estimated total annual cost of $89.1 billion dollars. If you are considering a $50,000 Total Knee Replacement Surgery don't do it without considering the risks.

Stem Cell Therapy for Rheumatoid Arthritis

Rheumatoid Arthritis is an auto-immune disease characterized by debilitating pain and joint destruction. Conventional drugs, including steroids, methotrexate and Humira cause serious long-term side effects. Stem Cells offer hope for joint regeneration.

Stem Cell Therapy for Lupus

Human Umbilical Cord Tissue is perhaps the greatest discovery and offers the highest hope for healing Systemic Lupus Erythematosus.

Stem Cell Therapy for COPD

Today more than 600 million people suffer from chronic obstructive pulmonary disease (COPD) worldwide. Although there is no cure for COPD, recent advancements in cellular therapy have made it possible to not only relieve symptoms, but to promote healing.